Consistent with this, liver-specific gain-of-function mutations in AMPKγ1 or direct targeting of AMPKγ1 with small molecules have shown protective effects against NASH [12, 47, 48] and liver glucose production [49], highlighting the importance of AMPKγ1 in the subsequent protective effects of AMPK activation. Here, PRKAA2 is linked to metabolic dysfunction-associated steatohepatitis.